{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Wu S"],"funding":["Natural Science Foundation of Shanghai Municipality","National Natural Science Foundation of China"],"pubmed_abstract":["Minimally invasive irreversible electroporation ablation shows promise for pancreatic cancer (PCa), but the high recurrence and metastasis rates pose a therapeutic challenge for loco-regional ablation treatment. Immunotherapy holds promise for preventing tumor recurrence, however, its efficacy against PCa remains limited. Here, using a preclinical model of PCa, it is identified that tumor development dramatically restructures the splenic immune landscape characterized by increased frequency of myeloid cells. Further, nanobiologics with high affinity for splenic myeloid cells using erythrocyte membrane fused with apoA1-modified liposomes are presented. Biocompatible CaCO<sub>3</sub> nanoparticles are incorporated to serve as a release reservoir of immunomodulatory therapeutics (muramyl dipe"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pagination":["e2413562"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12140294"],"repository":["biostudies-literature"],"pubmed_title":["Targeting Splenic Myeloid Cells with Nanobiologics to Prevent Postablative Pancreatic Cancer Recurrence via Inducing Antitumor Peripheral Trained Immunity."],"pmcid":["PMC12140294"],"funding_grant_id":["81725008","82171943","23ZR1449600","81927801"],"pubmed_authors":["Liu S","Sun X","Hou X","Xu H","Sun L","Shan X","Li S","Peng C","Wu S","Bo X","Yue W","Xu W","Huang B"],"additional_accession":[]},"is_claimable":false,"name":"Targeting Splenic Myeloid Cells with Nanobiologics to Prevent Postablative Pancreatic Cancer Recurrence via Inducing Antitumor Peripheral Trained Immunity.","description":"Minimally invasive irreversible electroporation ablation shows promise for pancreatic cancer (PCa), but the high recurrence and metastasis rates pose a therapeutic challenge for loco-regional ablation treatment. Immunotherapy holds promise for preventing tumor recurrence, however, its efficacy against PCa remains limited. Here, using a preclinical model of PCa, it is identified that tumor development dramatically restructures the splenic immune landscape characterized by increased frequency of myeloid cells. Further, nanobiologics with high affinity for splenic myeloid cells using erythrocyte membrane fused with apoA1-modified liposomes are presented. Biocompatible CaCO<sub>3</sub> nanoparticles are incorporated to serve as a release reservoir of immunomodulatory therapeutics (muramyl dipe","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-26T03:06:36.645Z","creation":"2025-07-26T03:06:36.645Z"},"accession":"S-EPMC12140294","cross_references":{"pubmed":["40289661"],"doi":["10.1002/advs.202413562"]}}